Quarterly report pursuant to Section 13 or 15(d)

STOCK BASED COMPENSATION (Details Narrative)

v3.10.0.1
STOCK BASED COMPENSATION (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 27, 2018
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Stock-based compensation expense   $ 179,050 $ 181,408 $ 1,557,163
Number of options granted       611,668
Option exercise price (in dollars per share)       $ 2.39
2010 Plan [Member]        
Option exercise price (in dollars per share)   $ 2.38    
Description of vesting rights  

Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones related to clinical trial progress.

   
2010 Plan [Member] | Dr. Steven C. Quay [Member]        
Number of options granted 2,300,000      
2010 Plan [Member] | Kyle Guse [Member]        
Number of options granted 700,000